Table 3.
Unadjusted and adjusted prevalence ratios (95% CIs) of having peripheral neuropathy, PVD, or both by cardiometabolic clustering and obesity categories in individuals aged ≥40 years, NHANES III, 2001–2004
| Nonobese (BMI <30 kg/m2) | Obese (BMI ≥30 kg/m2) |
||
|---|---|---|---|
| Without clustering |
With clustering | With and without clustering | |
| n | 503 | 1,148 | 809 |
| Peripheral neuropathy (alone)* | |||
| Proportion [% (SE)] | 4.9 (0.9) | 9.7 (0.8) | 10.9 (1.3) |
| Unadjusted prevalence ratio | 1 (Reference) | 2.07 (1.41–3.02) | 2.35 (1.55–3.56) |
| Adjusted prevalence ratio† | 1 (Reference) | 1.50 (1.00–2.25) | 2.20 (1.43–3.39) |
| PVD (alone)‡ | |||
| Proportion [% (SE)] | 3.2 (0.8) | 9.6 (1.0) | 10.3 (1.6) |
| Unadjusted prevalence ratio | 1 (Reference) | 3.25 (1.84–5.72) | 3.52 (2.08–5.94) |
| Adjusted prevalence ratio† | 1 (Reference) | 2.48 (1.38–4.44) | 3.10 (1.84–5.22) |
| LEDs (peripheral neuropathy and PVD combined) | |||
| Proportion [% (SE)] | 0.6 (0.2) | 2.3 (0.4) | 3.9 (0.8) |
| Unadjusted prevalence ratio | 1 (Reference) | 4.06 (1.62–10.18) | 7.05 (2.67–18.57) |
| Adjusted prevalence ratio† | 1 (Reference) | 2.62 (0.95–7.25) | 6.91 (2.64–18.06) |
*Peripheral neuropathy defined as one or more insensate sites on either foot.
†Adjusted for sex, age, and race/ethnicity.
‡PVD defined as an ABPI <0.90.